9783846504048 - Cost-effectiveness of Selected Immunisation Programs in Australia: Economic evaluation of influenza and hepatitis B immunization programs in Australia de Mogasale, ... (5 resultados)

Taschenbuch. Condición: Neu. Cost-effectiveness of Selected Immunisation Programs in Australia | Economic evaluation of influenza and hepatitis B immunization programs in Australia | Vittal Mogasale | Taschenbuch | 128 S. | Englisch | 2011 | LAP LAMBERT Academic Publishing | EAN 9783846504048 | Verantwortliche Person für die EU: BoD - Books on Demand, In de Tarpen 42, 22848 Norderstedt, info[at]bod[dot]de | Anbieter: preigu.

Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Health care costs are on the rise in Australia. Rational decisions using cost-effectiveness analyses are necessary to prioritise health interventions for the allocation of limited resources. Immunisation is an important component of preventive health care intervention and its cost-effectiveness analyses are useful in prioritising the choices. This book describes economic evaluation of two immunisation interventions in Australia: influenza and hepatitis B. We have analysed cost-effectiveness of reducing universal influenza vaccination age threshold to 50 from the current 65 using a decision tree model and cost-effectiveness of various hepatitis B infant vaccination strategies using a micro-simulation model. Here we describe the strength of the evidence to reduce universal influenza vaccination age threshold. Our results also suggest that the current hepatitis B vaccination strategy in Australia is an expensive one, but yields maximum health gain in general population. Is that the best choice How good is Australian hepatitis B immunization strategy for indigenous population Do we have alternative cost-effective choices This book tries to explore all these questions. 128 pp. Englisch.

Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Mogasale VittalDr.Vittal Mogasale, M.B.B.S., M.P.H., Ph.D., is a Physician, Public Health Professional and Health Economist who has worked for the control of communicable diseases over a decade in India. Now he works with Internatio.

Taschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Health care costs are on the rise in Australia. Rational decisions using cost-effectiveness analyses are necessary to prioritise health interventions for the allocation of limited resources. Immunisation is an important component of preventive health care intervention and its cost-effectiveness analyses are useful in prioritising the choices. This book describes economic evaluation of two immunisation interventions in Australia: influenza and hepatitis B. We have analysed cost-effectiveness of reducing universal influenza vaccination age threshold to 50 from the current 65 using a decision tree model and cost-effectiveness of various hepatitis B infant vaccination strategies using a micro-simulation model. Here we describe the strength of the evidence to reduce universal influenza vaccination age threshold. Our results also suggest that the current hepatitis B vaccination strategy in Australia is an expensive one, but yields maximum health gain in general population. Is that the best choice How good is Australian hepatitis B immunization strategy for indigenous population Do we have alternative cost-effective choices This book tries to explore all these questions.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 128 pp. Englisch.

Taschenbuch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Health care costs are on the rise in Australia. Rational decisions using cost-effectiveness analyses are necessary to prioritise health interventions for the allocation of limited resources. Immunisation is an important component of preventive health care intervention and its cost-effectiveness analyses are useful in prioritising the choices. This book describes economic evaluation of two immunisation interventions in Australia: influenza and hepatitis B. We have analysed cost-effectiveness of reducing universal influenza vaccination age threshold to 50 from the current 65 using a decision tree model and cost-effectiveness of various hepatitis B infant vaccination strategies using a micro-simulation model. Here we describe the strength of the evidence to reduce universal influenza vaccination age threshold. Our results also suggest that the current hepatitis B vaccination strategy in Australia is an expensive one, but yields maximum health gain in general population. Is that the best choice How good is Australian hepatitis B immunization strategy for indigenous population Do we have alternative cost-effective choices This book tries to explore all these questions.